Clinical Trials

GW’s cannabinoid fails in focal seizures trial

February 22, 2018 Pharma News HQ 0

The Phase IIa placebo-controlled study evaluated the efficacy and safety of GWP42006, which features cannabidivarin (CBDV) as the primary cannabinoid molecule, as add-on therapy in 162 adult patients with inadequately controlled focal seizures. Preliminary top-line […]